NetworkNewsBreaks

WednesdayMar 17, 2021 2:58 pm

NetworkNewsBreaks – Healthtech Solutions Inc. (HLTT) Announces Filing of Reg A with the SEC

Healthtech Solutions (OTC: HLTT), parent company of Medi-Scan Inc. and RevHeart Inc., today announced that it filed a Reg A with the Securities and Exchange Commission on Monday, March 8, 2021, to raise up to $75 million. According to the update, the company is offering up to a maximum of 1,500,000 shares of Series B preferred stock, $0.001 par value (“Preferred Stock”), at an offering price of $50 per share. The price will remain fixed for the duration of the Offering (the “Offered Shares”). The Offering will enable Healthtech Solutions to implement its three-pronged growth plan, which includes: the creation…

Continue Reading

WednesdayMar 17, 2021 2:36 pm

NetworkNewsBreaks – Uranium Energy Corp. (NYSE American: UEC) Announces Completion of Uranium Purchases, Additional Funding

Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company, has secured 800,000 pounds of additional U.S.-warehoused uranium; the shipment is comprised of a delivery in April consisting of 500,000 pounds and a second delivery scheduled for December consisting of 300,000 pounds; this uranium purchase follows a previously announced acquisition of 400,000 pounds. In total, UEC now has contracts to purchase 1,200,000 pounds of U3O8 at a volume-weighted average price of $28.94 per pound. In addition, the company has entered into definitive agreements with institutional investors to purchase 10,000,000 UEC common shares at $3.05 per share. The registered direct offering, which…

Continue Reading

WednesdayMar 17, 2021 1:24 pm

NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In addition, two to three more clinical sites will be selected for the trial, “A Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica.” “We have selected five U.S. sites to evaluate this…

Continue Reading

WednesdayMar 17, 2021 1:06 pm

NetworkNewsBreaks – Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) Eye-Net Mobile Enters Strategic Commercial Agreement

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, today announced that its wholly owned subsidiary, Eye-Net Mobile Ltd., has signed a commercial cooperation agreement with SaverOne 2014 Ltd. (TASE: SAVR), a leader in providing an effective solution to combat cell phone distracted driving. According to the update, Eye-Net will integrate its Eye-Net(TM) Protect solution in SaverOne’s product designed to prevent the use of texting applications by the driver while the vehicle is in motion. The integration is subject to certain tests and criteria to be determined by the parties. “Eye-Net is expanding its presence in…

Continue Reading

WednesdayMar 17, 2021 12:33 pm

NetworkNewsBreaks – Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Releases Annual, Q4 Financial Results

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) has released its financial numbers for the three- and twelve-month periods ended Dec. 31, 2020. Fourth-quarter financial and operational highlights of the report include a 41% increase in revenues from Q4 2019 ($9 million this quarter compared to $6.4 million in 2019); a gross profit increase of 37%, from a loss in Q4 2019 to $1.6 million in Q4 2020; an increase in silver production from 259,282 ounces in Q4 2019 to 355,581 in Q4 2020, resulting in the company’s strongest quarter of silver production since 2014. Fiscal year 2020 highlights included…

Continue Reading

WednesdayMar 17, 2021 11:38 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Advances Psychedelic IND Candidates, Announces Completion of 20th Preclinical Study

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced completion of its 20th preclinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to the update, Cybin, through collaboration with its partners and contractors, has completed key research studies both in-vitro and in-vivo. Based on proprietary Cybin technologies, more than 20 definitive research studies designed by the company’s scientists were completed in record time. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved…

Continue Reading

WednesdayMar 17, 2021 11:25 am

NetworkNewsBreaks – Friendable Inc. (FDBL) Mid-Month Update Indicates Impressive Growth

Friendable (OTC: FDBL), a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications, is seeing a significant increase in artists enrolling in its exclusive Fan Pass program, which is a live-streaming platform. The company also notes an impressive uptick in social media activity on the platform as well. Ten artists have joined the Fan Pass platform so far this month, which beats February numbers — and the month is only halfway over. In addition, the company noted that social media indicators show Fan Pass’ Facebook reach is up 96%, post engagements are…

Continue Reading

WednesdayMar 17, 2021 10:51 am

NetworkNewsBreaks – Augusta Gold Corp. (CSE: G) (OTCQB: AUGG) (FSE: 11B) Secures Conditional Approval for TSX Listing

Augusta Gold (CSE: G) (OTCQB: AUGG) (FSE: 11B) today announced its receipt of conditional approval to list its common shares on the Toronto Stock Exchange (the "TSX"). Concurrent with the TSX listing, Augusta Gold’s common shares will be de-listed from the Canadian Securities Exchange. Augusta Gold's trading symbol will remain "G" on the TSX. Final approval of the listing is subject to Augusta Gold meeting certain customary conditions required by the TSX. The company will issue an update upon confirmation on the effective date for commencement of trading of Augusta Gold common shares on the TSX. "We are very pleased…

Continue Reading

WednesdayMar 17, 2021 10:35 am

NetworkNewsBreaks – WELL Health Technologies Corp. (TSX: WELL) Releases Management Update, Announces Seed Investment

WELL Health Technologies (TSX: WELL), a company focused on consolidating and modernizing clinical and digital assets within the healthcare sector, has made to new appointment to its leadership team. The company named Atoussa Mahmoudpour as its chief legal officer and Ammar Shah as its vice president of mergers and acquisitions (“M&A”). Mahmoudpour has been serving as WELL’s vice president of legal affairs and compliance since September 2020; before coming to WELL, she held senior positions at several leading international firms, including Eversheds Sutherland LLP. Shah also joined the WELL team last September as director of M&A; his prior experience included serving as…

Continue Reading

WednesdayMar 17, 2021 10:31 am

NetworkNewsBreaks – MRVL Pet Pharmaceuticals(TM) Corp. to Collaborate with Altran for FDA Clinical Trials on Canine and Feline Cancer and Arthritis Treatment Products

MRVL Pet Pharmaceuticals(TM), a life sciences and technology company focused on the animal health sector, today announced its entry into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services on their U.S. FDA clinical trial process for canine and feline cancer and arthritis products. According to the update, renowned veterinary expert Dr. Albert Ahn was appointed as the chief researcher of the clinical trial that launched on Jan. 27, 2021, and is expected to consist of three phases and run until Dec. 30, 2022. Altran’s AVP of Regulatory Affairs, Quality and Compliance, Deborah…

Continue Reading